Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Inventory (2017 - 2025)

Historic Inventory for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $52.2 million.

  • Ultragenyx Pharmaceutical's Inventory rose 2045.97% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 2045.97%. This contributed to the annual value of $45.0 million for FY2024, which is 3249.43% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Inventory of $52.2 million as of Q3 2025, which was up 2045.97% from $46.5 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Inventory peaked at $52.2 million during Q3 2025, and registered a low of $12.5 million during Q1 2021.
  • For the 5-year period, Ultragenyx Pharmaceutical's Inventory averaged around $30.3 million, with its median value being $28.3 million (2023).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Inventory surged by 507.71% in 2021 and then soared by 6490.67% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Inventory (Quarter) stood at $16.2 million in 2021, then soared by 64.91% to $26.8 million in 2022, then rose by 26.91% to $34.0 million in 2023, then soared by 32.49% to $45.0 million in 2024, then rose by 15.98% to $52.2 million in 2025.
  • Its last three reported values are $52.2 million in Q3 2025, $46.5 million for Q2 2025, and $46.0 million during Q1 2025.